Skip to content
HowShorted

CORCEPT THERAPEUTICS INC short interest in 2021

In 2021, CORCEPT THERAPEUTICS INC's disclosed short interest ran from 10.16% of shares outstanding on 15 Jan 2021 to 14.66% on 31 Dec 2021, a change of +4.50 percentage points. The year's high was 16.84% on 15 Dec 2021 and its low 6.55% on 15 Jul 2021, averaging 8.81% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.78 days on 15 Apr 2021. Full history: CORCEPT THERAPEUTICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CORCEPT THERAPEUTICS INC in 2021

2021 in figures

Start of year
10.16% (15 Jan 2021)
End of year
14.66% (31 Dec 2021)
Change
+4.50 pp
High
16.84% (15 Dec 2021)
Low
6.55% (15 Jul 2021)
Average
8.81%
Highest days to cover
26.78 (15 Apr 2021)
SEC filings marked
9

Every report in 2021

CORCEPT THERAPEUTICS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202110.16%21.21
29 Jan 20219.75%24.27
12 Feb 20219.29%20.29results (8-K)
26 Feb 20219.29%19.1010-K filed, results (8-K)
15 Mar 20219.28%18.88
31 Mar 20219.01%22.29
15 Apr 20219.14%26.78
30 Apr 20218.62%26.62
14 May 20218.47%14.1310-Q filed, results (8-K)
28 May 20218.73%23.91
15 Jun 20218.48%18.60
30 Jun 20216.91%10.23
15 Jul 20216.55%18.01
30 Jul 20216.79%13.9710-Q filed, results (8-K)
13 Aug 20216.95%15.90
31 Aug 20217.17%20.21
15 Sep 20217.23%19.90
30 Sep 20217.30%16.97
15 Oct 20217.25%17.09
29 Oct 20218.00%16.73
15 Nov 20217.76%10.3310-Q filed, results (8-K)
30 Nov 20217.80%9.31
15 Dec 202116.84%4.53
31 Dec 202114.66%6.74

See also: CORCEPT THERAPEUTICS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.